# Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment

> **NCT07281833** · PHASE3 · RECRUITING · sponsor: **West German Study Group** · enrollment: 250 (estimated)

## Conditions studied

- Breast Cancer
- HR-positive Breast Cancer
- Advanced Breast Cancer
- Metastatic Breast Cancer
- HER2-negative Breast Cancer

## Interventions

- **DRUG:** Capivasertib

## Key facts

- **NCT ID:** NCT07281833
- **Lead sponsor:** West German Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-27
- **Primary completion:** 2030-03
- **Final completion:** 2030-03
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07281833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07281833, "Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07281833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*